Skip to main content

Table 5 Characteristics of included studies

From: The value of contrast‐enhanced ultrasound in determining the location of sentinel lymph nodes in breast cancer

Author, year

Patients (n)

Injection site

Injection dose

Identification rate

Number of SLNs

Localization method

Liu,2019 [24]

75

Intradermally inject at 3,6,9,12 o’clock around the arela

0.5ml x 4

94.67 %

(71/75)

116

Skin marked

Li,2019 [23]

453

Intradermally inject at 3,6,9,12 o’clock around the arela

0.6ml x 4

98.2 %

(445/453)

765

Skin marked

Kenzo,2019 [22]

75

Intradermally and subdermally inject at 3,6,9,12 o’clock around the arela

0.25ml x 8

100 %

(100/100)

92

Skin marked

Zhong,2018 [19]

126

Intradermally inject at outer upper quadrant near the areola

2ml

100 %

(126/126)

164

FNA

Xie,2015 [18]

101

Intradermally inject at outer upper quadrant near the areola

1.5ml

97.03 % (98/101)

115

Guidewire

Zhao,2018 [20]

110

Intradermally inject at the periareolar area

0.4ml

(One or two additional injections if failed)

96.4 %

(106/110)

134

Skin marked